🔎 Trials Near Me

Hjem › Nyrekreft (nyrecellekarcinom) › Texas › Houston

Kliniske studier for Nyrekreft (nyrecellekarcinom) i Houston, TX

35 studier for Nyrekreft (nyrecellekarcinom) søker deltakere på steder i og rundt Houston (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

RekruttererFase 1
  • NEO-811 Houston Site, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT07300241

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

RekruttererFase 1
  • University of Texas MD Anderson Cancer Center, Houston
  • NEXT Houston, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06270706

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
  • UT MD Anderson Cancer Center, Houston
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

RekruttererFase 1/2
  • University of Texas - MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05287945

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

RekruttererFase 2
  • UT MD Anderson Cancer Center, Houston
Alder 12 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT04981509

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

RekruttererFase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07594106

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

RekruttererFase 1/2
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT05267626

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

RekruttererFase 2
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT05048212

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

RekruttererFase 1/2
  • Texas Oncology - Gulf Coast, Houston
  • University of Texas MD Anderson Cancer Center, Houston
  • Texas Oncology - Gulf Coast, Houston
  • og 1 flere
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07227415

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

RekruttererFase 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT04969315

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

RekruttererFase 1
  • Md Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT07195916

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

RekruttererFase 3
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Houston Methodist Hospital, Houston
  • Methodist Willowbrook Hospital, Houston
  • og 1 flere
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06661720

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

RekruttererFase 2
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06940518

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

RekruttererFase 2
  • The University of Texas M. D. Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07187778

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

RekruttererFase 1/2
  • Research Site, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT07115043

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

RekruttererFase 1/2
  • Houston Methodist Hospital, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT04895709

A Study of MGC026 in Participants With Advanced Solid Tumors

RekruttererFase 1
  • The University of Texas MD Anderson Cancer Center, Houston
  • University of Texas Health Science Center at Houston, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT06242470

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

RekruttererFase 1
  • The University of Texas M. D. Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT07187869

IDOV-Immune for Advanced Solid Tumors

RekruttererFase 1
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06910657

PET/MR for Characterization of Renal Masses (RMs)

RekruttererObservasjonsstudie
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT06076538

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

RekruttererFase 1/2
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jul. 2026 · NCT05663710

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

RekruttererFase 1
  • UT MD Anderson, Houston
Alder 18 til 70 · Alle kjønn · Oppdatert 29. jul. 2026 · NCT07564232

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

RekruttererFase 1
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 16. jul. 2026 · NCT05092373

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

RekruttererFase 1
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 8. jun. 2026 · NCT06026410

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

RekruttererFase 1
  • University of Texas MD Anderson Cancer Center /ID# 252004, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 4. jun. 2026 · NCT04777994

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

RekruttererFase 2
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT07023432

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

RekruttererFase 2
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 20. mai 2026 · NCT06053658

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Rekrutterer
  • M D Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 15. apr. 2026 · NCT04693377

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

RekruttererFase 1/2
  • MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 13. apr. 2026 · NCT06362369

A Study of VET3-TGI in Patients With Solid Tumors

RekruttererFase 1
  • University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 7. apr. 2026 · NCT06444815

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

RekruttererFase 1
  • The University of Texas MD Anderson Cancer Center, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2025 · NCT06805825

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

RekruttererFase 3
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2025 · NCT04510597

A Study of IBI363 in Subjects with Advanced Solid Malignancies

RekruttererFase 2
  • MD Anderson Cancer Center-University of Texas, Houston
  • Oncology Consultants P.A., Houston
Alder 18 og eldre · Alle kjønn · Oppdatert 19. des. 2024 · NCT06281678

Nyrekreft (nyrecellekarcinom)-studier i andre byer

Andre studier i Houston

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.